Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Germline mutations of the CDKN2A gene are found in melanoma-prone families and individuals with multiple sporadic melanomas. The encoded protein, p16(INK4A), comprises four ankyrin-type repeats, and the mutations, most of which are missense and occur throughout the entire coding region, can disrupt the conformation of these structural motifs as well as the association of p16(INK4a) with its physiological targets, the cyclin-dependent kinases (CDKs) CDK4 and CDK6. Assessing pathogenicity of nonsynonymous mutations is critical to evaluate melanoma risk in carriers. In the current study, we investigate 20 CDKN2A germline mutations whose effects on p16(INK4A) structure and function have not been previously documented (Thr18_Ala19dup, Gly23Asp, Arg24Gln, Gly35Ala, Gly35Val, Ala57Val, Ala60Val, Ala60Arg, Leu65dup, Gly67Arg, Gly67_Asn71del, Glu69Gly, Asp74Tyr, Thr77Pro, Arg80Pro, Pro81Thr, Arg87Trp, Leu97Arg, Arg99Pro, and [Leu113Leu;Pro114Ser]). By considering genetic information, the predicted impact of each variant on the protein structure, its ability to interact with CDK4 and impede cell proliferation in experimental settings, we conclude that 18 of the 20 CDKN2A variants can be classed as loss of function mutations, whereas the results for two remain ambiguous. Discriminating between mutant and neutral variants of p16(INK4A) not only adds to our understanding of the functionally critical residues in the protein but provides information that can be used for melanoma risk prediction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 1×
“As observed in other inherited cancer conditions, such as breast cancer [Antoniou et al., 2003], CDKN2A mutation carriers in the overall population have a much lower melanoma risk than carriers within multiple case families [Begg et al., 2005].”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Self-citationRetinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899 · cited 1×
“It is also difficult to reconcile these observations with the consistent evidence that p16INK4A-mediated cell cycle arrest requires a functional retinoblastoma protein [Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995].”
BackgroundSelf-citationTakahashi, A., Ohtani, N., Yamakoshi, K., Iida, S.-I., Tahara, H., Nakayama, K., Nakayama, K. I., Ide, T., Saya, H., & Hara, E. (2006) · Nature Cell Biology · doi:10.1038/ncb1491 · Cited by 528
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Goldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0494 · Cited by 426
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280 · cited 1×
“…as well as two founder missense mutations: Arg24Pro [Harland et al., 1997; Ghiorzo et al., 2004], Val59Gly [Yakobson et al., 2003], Ala68Leu [Rizos et al., 2001a], Asn71Ser [Reymond and Brent, 1995; Ruas and Peters, 1998; Ranade et al., 1995; Della Torre et al., 2001], p.Met53Ile, and p.Gly101Trp.”
BackgroundINK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P. A., Lomax, M., James, M. C., Vatcheva, R., Bates, S., Vousden, K. H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf289 · Cited by 220 · cited 2×
“In physiological settings, increased expression of p16INK4a is associated with replicative senescence, now recognized as a defense mechanism against oncogenic and other forms of cellular stress [Brookes et al., 2002; Takahashi et al., 2006].”
BackgroundSelf-citation
Cited by
Romagosa, C., Simonetti, S., López-Vicente, L., Mazo, A., Lleonart, M. E., Castellvi, J., & Ramon y Cajal, S. (2011) · Oncogene · doi:10.1038/onc.2010.614 · Cited by 509
Kimura, H., Paranal, R. M., Nanda, N., Wood, L. D., Eshleman, J. R., Hruban, R. H., Goggins, M. G., Klein, A. P., The Familial Pancreatic Cancer Genome Sequencing Project, & Roberts, N. J. (2022) · eLife · doi:10.7554/elife.71137 · Cited by 23
“…and p.Gly101Arg did not demonstrate deleterious effects in previously reported CDK4 binding and cell proliferation assays (Jenkins et al., 2013; Kannengiesser et al., 2009; Miller et al., 2011). p.Gly122Val previously demonstrated CDK6 binding similar to WT CDKN2A, binding to CDK4 was…”
Background(2024) · doi:10.1093/database/baae031 · Cited by 4
Orlic-Milacic, M., Rothfels, K., Matthews, L., Wright, A., Jassal, B., Shamovsky, V., Trinh, Q., Gillespie, M., Sevilla, C., Tiwari, K., et al. (2023) · doi:10.1101/2023.10.18.562964 · Cited by 4
Metadata
- Authors
- Kannengiesser, C., Brookes, S., del Arroyo, A. G., Pham, D., Bombled, J., Barrois, M., Mauffret, O., Avril M, M.-F., Chompret, A., Lenoir, G. M., Sarasin, A., French Hereditary Melanoma Study Group, Peters, G., & Paillerets, B. B.-D.
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 30
- Issue
- 4
- Pages
- 564-574
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2029196645
- Cited by
- 41
- References
- 11
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.